**Poster Session B**  
Monday, May 20, 2019  
5:00 p.m.–7:30 p.m.

B01 **Validation of a novel cytologic biomarker for urothelial carcinoma.** Sruthi Babu, Renaissance School of Medicine, Stony Brook University, Stony Brook, NY, USA.

B02 **TP63 isoform expression landscape associations with bladder cancer patient outcomes.** Armand Bankhead, University of Michigan, Ann Arbor, MI, USA.

B03 **Identification of PTEN p.W274C as a potential biomarker to predict inferior survival in patients with limited stage small cell bladder cancer.** Earle Burgess, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.

B04 **Study on screening of new targets, specific recognition and intervention of bladder cancer.** Zhiming Cai, Shenzhen University, Shenzhen, Guangdong Province, China.

B05 **Basic research and translational medicine of bladder cancer in China.** Zhiming Cai, Shenzhen University, Shenzhen, Guangdong Province, China.

B06 **Pathological T1 substaging improves the identification of high-risk non-muscle invasive bladder cancer patients at risk of BCG-failure.** Florus Christiaan de Jong, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

B07 **A long non-coding RNA-based genomic classifier identifies a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.** Joep de Jong, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

B08 **MSH2 downregulation induces chemoresistance in bladder cancer.** Andrew Goodspeed, UC Denver AMC, Denver, CO, USA.

B09, PR08 **Genomic distinctions between metastatic lower and upper tract urothelial carcinoma revealed through rapid autopsy.** Andrew Hsieh, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

B10 **A simple immunohistochemical algorithm to evaluate molecular subtypes and clinical associations in non-muscle invasive bladder cancer.** Chelsea Jackson, Queen’s University, Kingston, ON, Canada.

B11 **Multi-omic interrogation of gemcitabine and cisplatin resistant bladder cancer cell lines identifies unique and shared mediators of chemosensitivity and resistance.** Robert Jones, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
B12 Characterization of the global proteome and phosphoproteome in cisplatin resistant bladder cancers revealed the CDK2 network as a potential therapeutic target. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B13 Acetate metabolism mediated by Acetyl-CoA synthetase 2 in cisplatin resistant bladder cancer. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B14 Epigenetic remodeling of cancer metabolisms in cisplatin resistant bladder cancer. Jayoung Kim, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

B15 Bladder cancer susceptibility polymorphisms and mortality from non-muscle and muscle invasive bladder cancer. Reno Leeming, Dartmouth College, Hanover, NH, USA.

B16 AGR2 is a marker of disease progression and a potential therapeutic target in non-muscle invasive bladder cancer. Andreia Maia, Champalimaud Centre for the Unknown, Lisbon, Portugal.

B17 Developing a multiplex imaging tool for cellular phenotyping to stratify non-muscle invasive bladder cancer patients. Paul Robson, The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.

B18 Molecular classification of NMIBC based on protein abundance. Rafael Stroggilos, Biomedical Research Foundation of the Academy of Athens, Athens, Greece.

B19, PR07 The genomic landscape of metastatic urothelial carcinoma from circulating tumor DNA. Gillian VandeKerkhove, Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.

B20 Characterization of tumor mutational landscape in smokers and non-smokers with urothelial carcinoma. Aleksandra Walasek, Memorial Sloan Kettering Cancer Center, New York, NY, United States.

B21 PTRF promotes cell survival and predicts disease progression in upper tract urothelial carcinoma. Hsin-Chih Yeh, Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

B22; PR02 Profiling intra-tumoral heterogeneity of bladder cancer subtypes at the single-cell level using machine-learning assisted histopathology. Andries Zijlstra, Vanderbilt University Medical Center, Nashville, TN, USA.

B24, PR06 Development of a biomarker-based nomogram to predict the pathologic response to neoadjuvant pembrolizumab in muscle-invasive urothelial bladder cancer (MIBC). Andrea Necchi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

B25, PR09 Gene expression profiling in wild type and mutant FGFR3 metastatic urothelial cancer treated with combination therapy with vofatamab and pembrolizumab. Woonyoung Choi, Johns Hopkins School of Medicine, Baltimore, MD, US.

B26 EV-301: A Phase 3 study evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have progressed on platinum-containing chemotherapy or anti-PD-(L)1 therapy. Amal Melhem-Bertrandt, Astellas Pharma, Inc., Northbrook, IL, USA.

B27 Photoluminescent nanoconjugates for molecular imaging of bladder cancer. Dmitry Polikarpov, Macquarie University, Sydney, NSW, Australia.

B28, PR01 Novel role of ketone body metabolism in acquired gemcitabine resistance. Krizia Rohena-Rivera, Cedars-Sinai Medical Center, Los Angeles, A, USA.

B29 Use of deep sequencing of urinary DNA as a biomarker of residual disease status at the time of radical cystectomy. Philip Abbosh, Fox Chase Cancer Center, Philadelphia, PA, USA.

B30 A living biomarker from urine to predict drug efficacy and recurrence of bladder cancer. Xuefeng Liu, Georgetown University, Washington, D.C., USA.